<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Exp Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Exp. Nephrol</journal-id><journal-title-group><journal-title>Clinical and Experimental Nephrology</journal-title></journal-title-group><issn pub-type="ppub">1342-1751</issn><issn pub-type="epub">1437-7799</issn><publisher><publisher-name>Springer Japan</publisher-name><publisher-loc>Tokyo</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27392909</article-id><article-id pub-id-type="pmc">5486454</article-id><article-id pub-id-type="publisher-id">1304</article-id><article-id pub-id-type="doi">10.1007/s10157-016-1304-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kimura</surname><given-names>Genjiro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1833-9075</contrib-id><name><surname>Kasahara</surname><given-names>Masato</given-names></name><address><phone>+81-744-29-8846</phone><email>kasa@naramed-u.ac.jp</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ueshima</surname><given-names>Kenji</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Sachiko</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yasuno</surname><given-names>Shinji</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fujimoto</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sato</surname><given-names>Toshiya</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Imamoto</surname><given-names>Miyuki</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kosugi</surname><given-names>Shinji</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Nakao</surname><given-names>Kazuwa</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label>Asahi Rosai Hospital, Owariasahi, Aichi Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0531 2775</institution-id><institution-id institution-id-type="GRID">grid.411217.0</institution-id><institution>Department of EBM Research, Institute of Advancement of Clinical and Translational Science, </institution><institution>Kyoto University Hospital, </institution></institution-wrap>Kyoto, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1773 1360</institution-id><institution-id institution-id-type="GRID">grid.474851.b</institution-id><institution>Institute for Clinical and Translational Science, </institution><institution>Nara Medical University Hospital, </institution></institution-wrap>840 Shijo-cho, Kashihara, Nara, Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 2033</institution-id><institution-id institution-id-type="GRID">grid.258799.8</institution-id><institution>Department of Biostatistics, </institution><institution>Kyoto University School of Public Health, </institution></institution-wrap>Kyoto, Japan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0643 028X</institution-id><institution-id institution-id-type="GRID">grid.468937.7</institution-id><institution>Department of Food and Nutritional Science, </institution><institution>Kobe Women&#x02019;s Junior College, </institution></institution-wrap>Kobe, Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 2033</institution-id><institution-id institution-id-type="GRID">grid.258799.8</institution-id><institution>Department of Medical Ethics/Medical Genetics, </institution><institution>Kyoto University School of Public Health, </institution></institution-wrap>Kyoto, Japan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 2033</institution-id><institution-id institution-id-type="GRID">grid.258799.8</institution-id><institution>Medical Innovation Center, </institution><institution>Kyoto University Graduate School of Medicine, </institution></institution-wrap>Kyoto, Japan </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>21</volume><issue>3</issue><fpage>417</fpage><lpage>424</lpage><history><date date-type="received"><day>12</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Dyslipidemia is a risk factor for the progression of chronic kidney disease (CKD). While conventional lipid lowering therapy provides a benefit to CKD management, the effect of statins on eGFR remains unclear.</p></sec><sec><title>Methods</title><p id="Par2">A prospective, multi-center, open-labeled, randomized trial. Total of 349 CKD patients with hyperlipidemia were randomized into 2 groups, and followed for 2&#x000a0;years. Group A included patients who were treated with atorvastatin. Group C were treated with conventional lipid lowering drugs other than statin. Primary endpoint was changes in eGFR. Secondary endpoints included changes in urinary albumin excretion, serum LDL-C, serum triglyceride, cardio-vascular events and all-cause mortality.</p></sec><sec><title>Results</title><p id="Par3">As the primary endpoint, eGFR decreased by 2.3&#x000a0;ml/min/1.73&#x000a0;m<sup>2</sup> in Group A and by 2.6&#x000a0;ml/min/1.73&#x000a0;m<sup>2</sup> in Group C, indicating that there was no difference in change of eGFR between the two groups. As secondary endpoints, atorvastatin succeeded to reduce serum LDL-C level significantly and rapidly, but conventional therapy did not. In fact, mean LDL-C level did not reach the target level of 100&#x000a0;mg/dl in Group C. Serum triglyceride was lowered only by atorvastatin, but not conventional drugs. The number of cardiovascular events and all-cause mortality did not differ between in two groups.</p></sec><sec><title>Conclusion</title><p id="Par4">The ASUCA (Assessment of Clinical Usefulness in CKD Patients with Atorvastatin) trial demonstrated that atorvastatin failed to exhibit reno-protections compared to conventional therapy in Japanese patients with dyslipidemia and CKD. It would be due in part to the ability of atorvastatin to more potently reduce serum LDL and triglycerides compared to conventional therapy.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chronic kidney disease (CKD)</kwd><kwd>Hyperlipidemia</kwd><kwd>Low-density lipoprotein cholesterol (LDL-C)</kwd><kwd>Statins</kwd><kwd>Reno-protective effect</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008648</institution-id><institution>Pfizer Foundation</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Japanese Society of Nephrology 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">An increased prevalence of chronic kidney disease (CKD) [<xref ref-type="bibr" rid="CR1">1</xref>] could be a future burden in our society. We must take countermeasures to prevent such epidemic. The Treating to New Targets (TNT) study was sub-analyzed to examine if the atorvastatin treatment at dose of either 80 or 10&#x000a0;mg for approximately 5&#x000a0;years could provide benefits on renal function in patients with coronary heart disease, and the study found that an estimated glomerular filtration rate (eGFR) was improved by atorvastatin with both doses of atorvastatin [<xref ref-type="bibr" rid="CR2">2</xref>]. Athyros&#x02019;s research group performed the subanalysis of the GREACE study in patients with coronary artery disease and lipid abnormality. They found that statin treatment was associated with improving eGFR while such benefit was not observed in patients without statin [<xref ref-type="bibr" rid="CR3">3</xref>]. Sandhu et al. also reported the positive effects of statins on renal function in their meta-analysis [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par6">While it is assumed that atorvastatin could also exhibit reno-protective effects, a large-scale clinical study focusing on eGFR as primary endpoint has not been conducted. The LORD trial is considering the renal function as a primary endpoint, but the sample size is small [<xref ref-type="bibr" rid="CR5">5</xref>]. Here, we conducted a large-scale clinical trial (ASUCA; assessment of clinical usefulness in CKD patients with atorvastatin) to investigate if atorvastatin could provide reno-protective effects in Japanese patients with CKD and dyslipidemia.</p></sec><sec id="Sec2"><title>Materials and methods</title><p id="Par7">The rationale and design of the ASUCA trial have already been published. [<xref ref-type="bibr" rid="CR6">6</xref>]. The ASUCA trial was a prospective, multi-center, open labeled, randomized trial performed in Japan. This study was registered at University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR) under the trial identification number UMIN000001778 and has been approved by the Ethics Committee at the Kyoto University Graduate School of Medicine (C-271). The trial was conducted in accordance with the Declaration of Helsinki Principles.</p><sec id="Sec3"><title>Participants</title><p id="Par8">The inclusion criteria in this trial included fulfillment of all of the following at enrollment: subjects should be (1) 40&#x000a0;&#x02264;&#x000a0;age&#x000a0;&#x0003c;&#x000a0;75; (2) not treated with statins; (3) with positive proteinuria and eGFR&#x000a0;&#x02265;60 (ml/min/1.73&#x000a0;m<sup>2</sup>); (4) eGFR&#x000a0;&#x0003c;60&#x000a0;ml/min/1.73&#x000a0;m<sup>2</sup> at enrolment; (5) LDL-C&#x000a0;&#x02265;140&#x000a0;mg/dl in subjects not taking any dyslipidemia-treating agents or LDL-C&#x000a0;&#x02265;100&#x000a0;mg/dl in those taking dyslipidemia-treating agents other than statins.</p><p id="Par9">The exclusion criteria were based on fulfillment of at least one of the following: (1) eGFR&#x000a0;&#x0003c;30&#x000a0;ml/min/1.73&#x000a0;m<sup>2</sup>; (2) systolic blood pressure&#x000a0;&#x02265;180&#x000a0;mmHg or diastolic blood pressure&#x000a0;&#x02265;110&#x000a0;mmHg; (3) hemoglobin A1c (HbA1c)&#x000a0;&#x02265;8.5&#x000a0;%; (4) familial hypercholesterolemia; (5) secondary hypercholesterolemia including nephrotic syndrome; (6) liver dysfunction including acute hepatitis, chronic active hepatitis, liver cirrhosis, and hepatoma; (7) past history of severe side effects of atorvastatin; (8) pregnancy, possibility of pregnancy, or breast-feeding woman.</p></sec><sec id="Sec4"><title>Study design</title><p id="Par10">After confirming the patient&#x02019;s eligibility, each patient who provided written informed consent was randomly assigned to the Group C (diet therapy with non-statin treatment) or Group A (diet therapy and atorvastatin treatment). The following factors were used for stratified randomization: (1) gender, (2) hypertension, (3) diabetes mellitus, (4) treatment with renin angiotensin aldosterone system (RAAS) inhibitors. The target serum LDL-C level was&#x000a0;&#x0003c;100&#x000a0;mg/dl. The follow-up period was 2&#x000a0;years. All patients basically received an adequate dietary advice of the non-face-to-face method. If dietary treatment in the Group C fails to reduce LDL-C level to the target level within the first 3&#x000a0;months, additional anti-dyslipidemic drugs except statins were allowed to be administered. The initial dose of atorvastatin in Group A was 10&#x000a0;mg/day and then adjusted to 5&#x02013;20&#x000a0;mg/day. If the LDL-C level did not reduce to the target in the Group A, additional anti-dyslipidemic drugs except statins and fibrates were allowed to be used.</p></sec><sec id="Sec5"><title>Outcome measures</title><p id="Par11">The primary outcome measure is the changes in eGFR (ml/min/1.73&#x000a0;m<sup>2</sup>) and based on serum creatinine measurement by the central laboratory. The secondary outcomes are (1) changes in urinary albumin/creatinine ratio (mg/g); (2) changes in serum LDL-C level; (3) changes in serum triglyceride level; (4) the number of total deaths, and (5) cerebro-cardiovascular events, which include cerebro-cardiovascular death and hospitalization due to cerebro-cardiovascular disease with revascularization, nonfatal cerebral bleeding and cerebral infarction, hemodialysis, and renal transplantation. Laboratory tests during a study period were performed at central laboratory (SRL, Inc., Tachikawa, Japan), and were scheduled to be done just before the start of treatment protocol, and 1, 3, 6, 9, 12, 18 and 24&#x000a0;months after the start of treatment protocol.</p></sec><sec id="Sec6"><title>Statistical considerations</title><p id="Par12">The primary endpoint is a comparison of the changes in eGFR between the two arms after 2&#x000a0;years of treatment, using covariance analysis with stratification factors in randomization (sex, with or without hypertension, with or without diabetes mellitus, with or without RAAS inhibitors) as covariates. This analysis is performed based on the principal of intention-to-treat population. The effects of statins on eGFR reported in the GREACE study [<xref ref-type="bibr" rid="CR3">3</xref>], the TNT study [<xref ref-type="bibr" rid="CR2">2</xref>], the MEGA study [<xref ref-type="bibr" rid="CR7">7</xref>], and meta-analyses [<xref ref-type="bibr" rid="CR4">4</xref>] ranged between 1.9 and 7&#x000a0;ml/min/1.73&#x000a0;m<sup>2</sup>. Based on these studies [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], we assume the standard deviation of changes per year in eGFR to be 12&#x000a0;ml/min/1.73&#x000a0;m<sup>2</sup> in both groups and the difference between the two arms to be 4&#x000a0;ml/min/1.73&#x000a0;m<sup>2</sup>. To achieve a power of 80&#x000a0;%, a total of 286 patients were required. Assuming the uncertainty of setting of parameters, we planned to enroll 165 patients per arm.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>The flow chart of the ASUCA trial</title><p id="Par13">Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows patient&#x02019;s flowchart of the ASUCA trial. All 437 patients were registered between April 2009 and March 2011. 88 patients were excluded by the assessment of eligibility. Among 437 patients registered, 349 were randomized after eligibility was assessed. The major reason for exclusion was ineligibility in laboratory tests before registration. Among the 349 patients, 15 were excluded due to no follow-up, declining to participate, and ineligibility found after randomization. Consequently, 334 patients were followed from January 2011 to May 2013 as FAS (full analysis set) population, consisted of 168 patients in the Group A and 166 patients in the Group C. Finally, PPS (per protocol set) population, consisted of 142 patients in the Group A and 150 patients in the Group C.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Patient&#x02019;s flowchart in the ASUCA trial</p></caption><graphic xlink:href="10157_2016_1304_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec9"><title>Baseline</title><p id="Par14">Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> show baseline characteristics and laboratory tests of the 334 patients. In Group A and Group C, mean ages of subjects were 63.2 and 63.1&#x000a0;years, respectively. A percentage of hypertension at baseline was 60.7&#x000a0;% in Group A and 62.7&#x000a0;% in Group C. Prevalence of diabetic patients were 34.5 and 33.1&#x000a0;%. Past history of cerebro-cardiac diseases were within 10&#x000a0;%. Mean eGFR at baseline in Group A and Group C were 56.0 and 54.0&#x000a0;ml/min/1.73&#x000a0;m<sup>2</sup>. Mean LDL-C and log-transformed mean urinary albumin excretion were 142.2 and 145.9&#x000a0;mg/dl, 3.60 and 3.89&#x000a0;mg/g Cr.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patients&#x02019; characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">
<italic>n</italic> (%)/mean&#x000a0;&#x000b1;&#x000a0;SD</th></tr><tr><th align="left">Group A (<italic>n</italic>&#x000a0;=&#x000a0;168)</th><th align="left">Group C (<italic>n</italic>&#x000a0;=&#x000a0;166)</th></tr></thead><tbody><tr><td align="left">Male</td><td align="left">105 (62.5)</td><td align="left">108 (65.1)</td></tr><tr><td align="left">Age, years<sup>a</sup>
</td><td align="left">63.2&#x000a0;&#x000b1;&#x000a0;7.9</td><td align="left">63.1&#x000a0;&#x000b1;&#x000a0;8.3</td></tr><tr><td align="left" colspan="3">Disease complication (with duplication)</td></tr><tr><td align="left">&#x000a0;Hypertension</td><td align="left">102 (60.7)</td><td align="left">104 (62.7)</td></tr><tr><td align="left">&#x000a0;Diabetes</td><td align="left">58 (34.5)</td><td align="left">55 (33.1)</td></tr><tr><td align="left">&#x000a0;Diabetic neuropathy</td><td align="left">13 (7.7)</td><td align="left">5 (3.0)</td></tr><tr><td align="left">&#x000a0;Diabetic retinopathy</td><td align="left">11 (6.5)</td><td align="left">11 (6.6)</td></tr><tr><td align="left">&#x000a0;Glomerulonephritis</td><td align="left">18 (10.7)</td><td align="left">20 (12.0)</td></tr><tr><td align="left" colspan="3">Past history (with duplication)</td></tr><tr><td align="left">&#x000a0;Cerebrovascular accident</td><td align="left">8 (4.8)</td><td align="left">11 (6.6)</td></tr><tr><td align="left">&#x000a0;Myocardial infarction</td><td align="left">0 (0.0)</td><td align="left">2 (1.2)</td></tr><tr><td align="left">&#x000a0;Angina pectoris</td><td align="left">2 (1.2)</td><td align="left">2 (1.2)</td></tr><tr><td align="left">Heart failure</td><td align="left">3 (1.8)</td><td align="left">4 (2.4)</td></tr><tr><td align="left">&#x000a0;Arteriosclerosis obliterans</td><td align="left">4 (2.4)</td><td align="left">1 (0.6)</td></tr><tr><td align="left">Normal ECG<sup>b</sup>
</td><td align="left">135 (80.8)</td><td align="left">125 (76.2)</td></tr><tr><td align="left" colspan="3">Smoker</td></tr><tr><td align="left">&#x000a0;Current</td><td align="left">19 (11.3)</td><td align="left">28 (16.9)</td></tr><tr><td align="left">&#x000a0;Past</td><td align="left">31 (18.5)</td><td align="left">28 (16.9)</td></tr><tr><td align="left" colspan="3">Alcohol drinker</td></tr><tr><td align="left">&#x000a0;Current</td><td align="left">70 (41.7)</td><td align="left">64 (38.6)</td></tr><tr><td align="left">&#x000a0;Past</td><td align="left">7 (4.2)</td><td align="left">3 (1.8)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Mean&#x000a0;&#x000b1;&#x000a0;SD</p><p>
<sup>b</sup>Normal electrocardiogram</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Baseline laboratory test</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2">Mean&#x000a0;&#x000b1;&#x000a0;SD</th></tr><tr><th align="left">Group A (<italic>n</italic>&#x000a0;=&#x000a0;168)</th><th align="left">Group C (<italic>n</italic>&#x000a0;=&#x000a0;166)</th></tr></thead><tbody><tr><td align="left">eGFR<sup>a</sup>, ml/mm/1.73&#x000a0;m<sup>2</sup>
</td><td char="&#x000b1;" align="char">56.0&#x000a0;&#x000b1;&#x000a0;11.6</td><td char="&#x000b1;" align="char">54.0&#x000a0;&#x000b1;&#x000a0;11.6</td></tr><tr><td align="left">LDL-C, mg/dl</td><td char="&#x000b1;" align="char">142.2&#x000a0;&#x000b1;&#x000a0;26.7</td><td char="&#x000b1;" align="char">145.9&#x000a0;&#x000b1;&#x000a0;29.4</td></tr><tr><td align="left">TG, mg/dl</td><td char="&#x000b1;" align="char">172.1&#x000a0;&#x000b1;&#x000a0;98.2</td><td char="&#x000b1;" align="char">189.9&#x000a0;&#x000b1;&#x000a0;145.2</td></tr><tr><td align="left">HDL-C, mg/dl</td><td char="&#x000b1;" align="char">52.6&#x000a0;&#x000b1;&#x000a0;13.8</td><td char="&#x000b1;" align="char">51.0&#x000a0;&#x000b1;&#x000a0;12.1</td></tr><tr><td align="left">U-Alb<sup>b</sup>, mg/g creatinine</td><td char="&#x000b1;" align="char">248.1&#x000a0;&#x000b1;&#x000a0;647.9</td><td char="&#x000b1;" align="char">373.4&#x000a0;&#x000b1;&#x000a0;842.1</td></tr><tr><td align="left">Log-transformed U-Alb, mg/g creatinine</td><td char="&#x000b1;" align="char">3.60&#x000a0;&#x000b1;&#x000a0;1.95</td><td char="&#x000b1;" align="char">3.89&#x000a0;&#x000b1;&#x000a0;2.09</td></tr><tr><td align="left">SBP, mmHg</td><td char="&#x000b1;" align="char">134.2&#x000a0;&#x000b1;&#x000a0;17.3</td><td char="&#x000b1;" align="char">132.2&#x000a0;&#x000b1;&#x000a0;15.3</td></tr><tr><td align="left">DPB, mmHg</td><td char="&#x000b1;" align="char">76.2&#x000a0;&#x000b1;&#x000a0;10.9</td><td char="&#x000b1;" align="char">77.4&#x000a0;&#x000b1;&#x000a0;10.2</td></tr><tr><td align="left">Heart rate, min<sup>&#x02212;1</sup>
</td><td char="&#x000b1;" align="char">69.9&#x000a0;&#x000b1;&#x000a0;11.0</td><td char="&#x000b1;" align="char">72.3&#x000a0;&#x000b1;&#x000a0;11.2</td></tr><tr><td align="left">BMI, kg/m<sup>2</sup>
</td><td char="&#x000b1;" align="char">25.6&#x000a0;&#x000b1;&#x000a0;3.4</td><td char="&#x000b1;" align="char">25.6&#x000a0;&#x000b1;&#x000a0;3.9</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Estimated glomerular filtration rate</p><p>
<sup>b</sup>Urinary albumin excretion</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Concomitant treatment</title><p id="Par15">Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows concomitant treatments during the study. Patients who took lipid lowering agents other than statin were one-quarters at baseline, 83.3&#x000a0;% at the end of follow-up in Group C. Ezetimibe accounted 72.0&#x000a0;% of the patients in Group C. Two-thirds were treated by RAAS inhibitors during the study.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Concomitant treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="4">
<italic>n</italic> (%)</th></tr><tr><th align="left" colspan="2">Baseline</th><th align="left" colspan="2">End of follow-up</th></tr><tr><th align="left">Group A</th><th align="left">Group C</th><th align="left">Group A</th><th align="left">Group C</th></tr></thead><tbody><tr><td align="left">Lipid lowering agents other than statin</td><td char="(" align="char">36 (21.4&#x000a0;%)</td><td char="(" align="char">40 (24.1&#x000a0;%)</td><td char="(" align="char">7 (4.9&#x000a0;%)</td><td char="(" align="char">125 (83.3&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Fibrate</td><td char="(" align="char">13 (7.7&#x000a0;%)</td><td char="(" align="char">17 (10.2&#x000a0;%)</td><td char="(" align="char">0 (0.0&#x000a0;%)</td><td char="(" align="char">26 (17.3&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Probucol</td><td char="(" align="char">0 (0.0&#x000a0;%)</td><td char="(" align="char">1 (0.6&#x000a0;%)</td><td char="(" align="char">0 (0.0&#x000a0;%)</td><td char="(" align="char">8 (5.3&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Ezetimibe</td><td char="(" align="char">13 (7.7&#x000a0;%)</td><td char="(" align="char">12 (7.2&#x000a0;%)</td><td char="(" align="char">4 (2.8&#x000a0;%)</td><td char="(" align="char">108 (72.0&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Resin</td><td char="(" align="char">1 (0.6&#x000a0;%)</td><td char="(" align="char">2 (1.2&#x000a0;%)</td><td char="(" align="char">1 (0.7&#x000a0;%)</td><td char="(" align="char">7 (4.7&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Others</td><td char="(" align="char">9 (5.4&#x000a0;%)</td><td char="(" align="char">14 (8.4&#x000a0;%)</td><td char="(" align="char">2 (1.4&#x000a0;%)</td><td char="(" align="char">24 (16.9&#x000a0;%)</td></tr><tr><td align="left">Blood pressure lowering drugs</td><td char="(" align="char">125 (74.4&#x000a0;%)</td><td char="(" align="char">125 (75.3&#x000a0;%)</td><td char="(" align="char">107 (75.4&#x000a0;%)</td><td char="(" align="char">115 (76.7&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;ARB<sup>a</sup>
</td><td char="(" align="char">96 (57.1&#x000a0;%)</td><td char="(" align="char">105 (63.3&#x000a0;%)</td><td char="(" align="char">83 (58.5&#x000a0;%)</td><td char="(" align="char">94 (62.7&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;ACE-I<sup>b</sup>
</td><td char="(" align="char">10 (6.0&#x000a0;%)</td><td char="(" align="char">15 (9.0&#x000a0;%)</td><td char="(" align="char">9 (6.3&#x000a0;%)</td><td char="(" align="char">14 (9.3&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Diuretics</td><td char="(" align="char">29 (17.3&#x000a0;%)</td><td char="(" align="char">24 (14.5&#x000a0;%)</td><td char="(" align="char">22 (15.5&#x000a0;%)</td><td char="(" align="char">20 (13.3&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;&#x003b1; blocker</td><td char="(" align="char">4 (2.4&#x000a0;%)</td><td char="(" align="char">6 (3.6&#x000a0;%)</td><td char="(" align="char">5 (3.5&#x000a0;%)</td><td char="(" align="char">5 (3.3&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;&#x003b2; blocker</td><td char="(" align="char">17 (10.1&#x000a0;%)</td><td char="(" align="char">26 (15.7&#x000a0;%)</td><td char="(" align="char">15 (10.6&#x000a0;%)</td><td char="(" align="char">23 (15.3&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Calcium antagonists</td><td char="(" align="char">76 (45.2&#x000a0;%)</td><td char="(" align="char">73 (44.0&#x000a0;%)</td><td char="(" align="char">67 (47.2&#x000a0;%)</td><td char="(" align="char">68 (45.3&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Aldosterone antagonist</td><td char="(" align="char">6 (3.6&#x000a0;%)</td><td char="(" align="char">5 (3.0&#x000a0;%)</td><td char="(" align="char">6 (4.2&#x000a0;%)</td><td char="(" align="char">5 (3.3&#x000a0;%)</td></tr><tr><td align="left">&#x000a0;Others</td><td char="(" align="char">3 (1.8&#x000a0;%)</td><td char="(" align="char">2 (1.2&#x000a0;%)</td><td char="(" align="char">2 (1.4&#x000a0;%)</td><td char="(" align="char">2 (1.3&#x000a0;%)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Angiotensin 2 receptor blockers</p><p>
<sup>b</sup>Angiotensin converting enzyme inhibitor</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Changes in the lipid profile</title><p id="Par16">The time course of LDL-C is shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. LDL-C decreased significantly and rapidly in Group A and the level of LDL-C fulfilled the protocol requirement. The final average dosage of atorvastatin at the end of follow-up period was 10.5&#x000a0;mg. In contrast, the conventional therapy slowly but significantly decreased in serum LDL-C in Group C compared to Group A. In Group C, the LDL-C concentration ended up to 116.0&#x000a0;mg/dl. While this level, met recommendation of Japanese Society of Nephrology, it did not reach the target level of 100&#x000a0;mg/dl. TG was significantly reduced only by atorvastatin, but not conventional drugs (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Atorvastatin lowered serum HDL levels (&#x02212;2.2&#x000a0;mg/dl), whereas control treatment reduced it by 2.9&#x000a0;mg/dl. The difference on the HDL lowering effects between two groups did not reach statistical significance. In addition, it was found that serum HDL levels were not associated with GFR in our study (data not shown).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Time course of LDL-C concentration. <italic>Solid line</italic> and <italic>dashed line</italic> represent Group A (atorvastatin) and B (control), respectively. <italic>Dotted line</italic> represents recommended value of Japanese society of nephrology. <italic>Error bars</italic> represent standard deviation. *<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05: each point value vs. baseline value, <sup>#</sup>
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05: group A vs group C</p></caption><graphic xlink:href="10157_2016_1304_Fig2_HTML" id="MO2"/></fig>
<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Time course of serum TG. <italic>Solid line</italic> and <italic>dashed line</italic> represent Group A (atorvastatin) and C (control), respectively. <italic>Error bars</italic> represent standard deviation. *<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05: each points value vs. baseline value, <sup>#</sup>
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05: Group A vs. Group C</p></caption><graphic xlink:href="10157_2016_1304_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec12"><title>Changes in the GFR</title><p id="Par17">As shown in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, the changes in mean eGFR (&#x02212;2.6&#x000a0;ml/min/1.73&#x000a0;m<sup>2</sup>) in Group C was similar to that (&#x02212;2.3&#x000a0;ml/min/1.73&#x000a0;m2) in Group A. The difference in mean eGFR changes between two groups was not reach statistical significant (<italic>p</italic>&#x000a0;=&#x000a0;0.851). Interestingly, a significant reduction of eGFR compared to baseline level was observed at 24&#x000a0;months in Group A, whereas it was detected from 12&#x000a0;month in Group C. A level of eGFR was identical between two groups at 24&#x000a0;month (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). There was significant different in the changes of albuminuria in Group C (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). There was no significant difference in composite of cardiovascular events and all-cause of death between Group A and Group C (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). Prespecified subgroup analysis on change in eGFR is shown in Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>. There was a statistically significant difference between Group A and Group C (<italic>p</italic>&#x000a0;=&#x000a0;0.015) only in the subgroup of taking a lipid lowering drugs at enrollment.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Changes in mean eGFR levels</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Changes in eGFR</th><th align="left" colspan="2">Mean&#x000a0;&#x000b1;&#x000a0;SD</th></tr><tr><th align="left">Group A (<italic>n</italic>&#x000a0;=&#x000a0;133)</th><th align="left">Group C (<italic>n</italic>&#x000a0;=&#x000a0;146)</th></tr></thead><tbody><tr><td align="left">eGFR<sup>a</sup> at baseline</td><td align="left">56.2&#x000a0;&#x000b1;&#x000a0;11.2</td><td align="left">54.4&#x000a0;&#x000b1;&#x000a0;11.6</td></tr><tr><td align="left">eGFR after 2&#x000a0;years of treatment</td><td align="left">53.9&#x000a0;&#x000b1;&#x000a0;13.2</td><td align="left">51.9&#x000a0;&#x000b1;&#x000a0;13.7</td></tr><tr><td align="left">Difference</td><td align="left">&#x02212;2.3&#x000a0;&#x000b1;&#x000a0;8.7</td><td align="left">&#x02212;2.6&#x000a0;&#x000b1;&#x000a0;8.8</td></tr><tr><td align="left">Estimated difference (95&#x000a0;% CI)</td><td align="left" colspan="2">0.19 (&#x02212;1.85 to 2.24)</td></tr><tr><td align="left">
<italic>P</italic> value</td><td align="left" colspan="2">0.851</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Estimated glomerular filtration rate</p></table-wrap-foot></table-wrap>
<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Time course of eGFR changes. <italic>Solid line</italic> and <italic>dashed line</italic> represent Group A (atorvastatin) and C (control), respectively. *<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05: each point value vs. baseline value</p></caption><graphic xlink:href="10157_2016_1304_Fig4_HTML" id="MO4"/></fig>
<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Time course of log-transformed urinary albumin excretion. <italic>Solid line</italic> and <italic>dashed line</italic> represent Group A (atorvastatin) and C (control), respectively. <italic>Error bars</italic> represent standard deviation. *<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05: each point value vs. baseline value</p></caption><graphic xlink:href="10157_2016_1304_Fig5_HTML" id="MO5"/></fig>
<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>The number of cerebro-cardiovascular events</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Group A (<italic>n</italic>&#x000a0;=&#x000a0;168)</th><th align="left">Group C (<italic>n</italic>&#x000a0;=&#x000a0;166)</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Cardiovascular events</td><td char="(" align="char">4 (2.4&#x000a0;%)</td><td char="(" align="char">2 (1.2&#x000a0;%)</td><td align="left">0.685</td></tr><tr><td align="left">&#x000a0;Sudden death</td><td char="(" align="char">1 (0.6&#x000a0;%)</td><td char="(" align="char">0 (0.0&#x000a0;%)</td><td align="left"/></tr><tr><td align="left">&#x000a0;AMI<sup>a</sup>
</td><td char="(" align="char">0 (0.0&#x000a0;%)</td><td char="(" align="char">1 (0.6&#x000a0;%)</td><td align="left"/></tr><tr><td align="left">&#x000a0;AP<sup>b</sup>
</td><td char="(" align="char">1 (0.6&#x000a0;%)</td><td char="(" align="char">0 (0.0&#x000a0;%)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Stroke</td><td char="(" align="char">2 (0.6&#x000a0;%)</td><td char="(" align="char">0 (0.0&#x000a0;%)</td><td align="left"/></tr><tr><td align="left">&#x000a0;ESRD<sup>c</sup>
</td><td char="(" align="char">1 (0.6&#x000a0;%)</td><td char="(" align="char">1 (0.6&#x000a0;%)</td><td align="left"/></tr><tr><td align="left">All-cause death</td><td char="(" align="char">1 (0.6&#x000a0;%)</td><td char="(" align="char">1 (0.6&#x000a0;%)</td><td align="left">1.000</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Acute myocardial infarction</p><p>
<sup>b</sup>Angina pectoris</p><p>
<sup>c</sup>End stage renal disease</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab6"><label>Table&#x000a0;6</label><caption><p>Prespecified subgroup analysis on change in eGFR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">
<italic>n</italic>
</th><th align="left">Estimated difference</th><th align="left">95&#x000a0;% CI</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="5">Sex</td></tr><tr><td align="left">&#x000a0;Male</td><td char="." align="char">213</td><td char="." align="char">&#x02212;0.25</td><td align="left">&#x02212;2.91 to 2.39</td><td char="." align="char">0.847</td></tr><tr><td align="left">&#x000a0;Female</td><td char="." align="char">121</td><td char="." align="char">1.25</td><td align="left">&#x02212;1.91 to 4.43</td><td char="." align="char">0.434</td></tr><tr><td align="left" colspan="5">Age, years</td></tr><tr><td align="left">&#x000a0;&#x0003c;65</td><td char="." align="char">167</td><td char="." align="char">&#x02212;0.37</td><td align="left">&#x02212;3.55 to 2.81</td><td char="." align="char">0.817</td></tr><tr><td align="left">&#x000a0;&#x02265;65</td><td char="." align="char">167</td><td char="." align="char">0.48</td><td align="left">&#x02212;2.17 to 3.14</td><td char="." align="char">0.717</td></tr><tr><td align="left" colspan="5">BMI, kg/m<sup>2</sup>
</td></tr><tr><td align="left">&#x000a0;&#x0003c;25</td><td char="." align="char">168</td><td char="." align="char">0.63</td><td align="left">&#x02212;2.11 to 3.39</td><td char="." align="char">0.648</td></tr><tr><td align="left">&#x000a0;&#x02265;25</td><td char="." align="char">166</td><td char="." align="char">&#x02212;0.16</td><td align="left">&#x02212;3.24 to 2.9</td><td char="." align="char">0.914</td></tr><tr><td align="left" colspan="5">HDL-C, mg/dl</td></tr><tr><td align="left">&#x000a0;&#x02265;40 (50: female)</td><td char="." align="char">238</td><td char="." align="char">0.42</td><td align="left">&#x02212;1.93 to 2.78</td><td char="." align="char">0.722</td></tr><tr><td align="left">&#x000a0;&#x0003c;40 (50: female)</td><td char="." align="char">85</td><td char="." align="char">&#x02212;0.38</td><td align="left">&#x02212;4.62 to 3.85</td><td char="." align="char">0.857</td></tr><tr><td align="left" colspan="5">LDL-C, mg/dl</td></tr><tr><td align="left">&#x000a0;&#x0003c;140</td><td char="." align="char">142</td><td char="." align="char">0</td><td align="left">&#x02212;3.06 to 3.05</td><td char="." align="char">0.999</td></tr><tr><td align="left">&#x000a0;&#x02265;140</td><td char="." align="char">181</td><td char="." align="char">0.52</td><td align="left">&#x02212;2.21 to 3.26</td><td char="." align="char">0.706</td></tr><tr><td align="left" colspan="5">TG, mg/dl</td></tr><tr><td align="left">&#x000a0;&#x0003c;150</td><td char="." align="char">148</td><td char="." align="char">0.99</td><td align="left">&#x02212;1.96 to 3.95</td><td char="." align="char">0.506</td></tr><tr><td align="left">&#x000a0;&#x02265;150</td><td char="." align="char">175</td><td char="." align="char">&#x02212;0.52</td><td align="left">&#x02212;3.39 to 2.35</td><td char="." align="char">0.719</td></tr><tr><td align="left" colspan="5">U-Alb<sup>a</sup>, mg/g creatinine</td></tr><tr><td align="left">&#x000a0;&#x0003c;30</td><td char="." align="char">168</td><td char="." align="char">&#x02212;0.02</td><td align="left">&#x02212;2.8 to 2.75</td><td char="." align="char">0.986</td></tr><tr><td align="left">&#x000a0;&#x02265;30</td><td char="." align="char">154</td><td char="." align="char">0</td><td align="left">&#x02212;2.96 to 2.96</td><td char="." align="char">0.999</td></tr><tr><td align="left" colspan="5">U-Alb, mg/g creatinine</td></tr><tr><td align="left">&#x000a0;&#x0003c;300</td><td char="." align="char">256</td><td char="." align="char">0.24</td><td align="left">&#x02212;1.84 to 2.33</td><td char="." align="char">0.819</td></tr><tr><td align="left">&#x000a0;&#x0003e;300</td><td char="." align="char">66</td><td char="." align="char">&#x02212;1.52</td><td align="left">&#x02212;7.02 to 3.98</td><td char="." align="char">0.581</td></tr><tr><td align="left" colspan="5">eGFR<sup>b</sup>, ml/min/1.73<sup>2</sup>
</td></tr><tr><td align="left">&#x000a0;&#x02265;45</td><td char="." align="char">263</td><td char="." align="char">0.36</td><td align="left">&#x02212;1.71 to 2.44</td><td char="." align="char">0.727</td></tr><tr><td align="left">&#x000a0;&#x0003c;45</td><td char="." align="char">60</td><td char="." align="char">1.22</td><td align="left">&#x02212;5.59 to 8.03</td><td char="." align="char">0.719</td></tr><tr><td align="left" colspan="5">hs CRP<sup>c</sup>, ng/ml</td></tr><tr><td align="left">&#x000a0;&#x0003c;634 (median)</td><td char="." align="char">161</td><td char="." align="char">0.51</td><td align="left">&#x02212;2.12 to 3.15</td><td char="." align="char">0.698</td></tr><tr><td align="left">&#x000a0;&#x02265;634 (median)</td><td char="." align="char">162</td><td char="." align="char">&#x02212;0.28</td><td align="left">&#x02212;3.42 to 2.84</td><td char="." align="char">0.856</td></tr><tr><td align="left" colspan="5">Diabetes</td></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">221</td><td char="." align="char">0.46</td><td align="left">&#x02212;1.76 to 2.69</td><td char="." align="char">0.682</td></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">113</td><td char="." align="char">&#x02212;0.06</td><td align="left">&#x02212;4.22 to 4.13</td><td char="." align="char">0.977</td></tr><tr><td align="left" colspan="5">Hypertension</td></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">128</td><td char="." align="char">&#x02212;0.17</td><td align="left">&#x02212;3.32 to 2.98</td><td char="." align="char">0.917</td></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">206</td><td char="." align="char">0.49</td><td align="left">&#x02212;2.20 to 3.18</td><td char="." align="char">0.720</td></tr><tr><td align="left" colspan="5">LVH<sup>d</sup>
</td></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">310</td><td char="." align="char">0.27</td><td align="left">&#x02212;1.81 to 2.36</td><td char="." align="char">0.796</td></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">21</td><td char="." align="char">&#x02212;3.21</td><td align="left">&#x02212;17.57 to 11.13</td><td char="." align="char">0.619</td></tr><tr><td align="left" colspan="5">History of CVD<sup>e</sup>
</td></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">277</td><td char="." align="char">0.08</td><td align="left">&#x02212;2.08 to 2.24</td><td char="." align="char">0.94</td></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">57</td><td char="." align="char">0.46</td><td align="left">&#x02212;5.49 to 6.43</td><td char="." align="char">0.874</td></tr><tr><td align="left" colspan="5">Lipid lowering drugs at enrollment</td></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">258</td><td char="." align="char">&#x02212;1.31</td><td align="left">&#x02212;3.56 to 0.93</td><td char="." align="char">0.249</td></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">76</td><td char="." align="char">5.68</td><td align="left">1.11 to 10.25</td><td char="." align="char">0.015</td></tr><tr><td align="left" colspan="5">RAAS inhibitor<sup>f</sup> at enrollment</td></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">116</td><td char="." align="char">0</td><td align="left">&#x02212;3.59 to 3.59</td><td char="." align="char">0.998</td></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">218</td><td char="." align="char">0.28</td><td align="left">&#x02212;2.27 to 2.85</td><td char="." align="char">0.824</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Urinary albumin excretion</p><p>
<sup>b</sup>Estimated glomerular filtration rate</p><p>
<sup>c</sup>High sensitivity c-reactive protein</p><p>
<sup>d</sup>Left ventricular hypertrophy</p><p>
<sup>e</sup>Cardio vascular disease</p><p>
<sup>f</sup>Renin angiotensin aldosterone system inhibitor</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par18">Statin might protect kidney in addition to lowering serum cholesterol level. Although precise mechanisms for its reno-protection remains unclear, one of the potential mechanisms could be an increase in endothelial NO production [<xref ref-type="bibr" rid="CR8">8</xref>]. A reduction in vascular resistance [<xref ref-type="bibr" rid="CR9">9</xref>] and increase in renal blood flow with higher cardiac output [<xref ref-type="bibr" rid="CR10">10</xref>] might be accounted for by such increase in endothelial NO. Blocking mesangial proliferation [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>] and stabilizing vascular plaques [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] by statin also likely contribute to slow the progression of renal disease. Among several types of statins, atorvastatin, is a lipid-soluble type statin, might be more potent to block the development of kidney disease. In fact, a recent study has demonstrated that atorvastatin was able to improve eGFR in patients with diabetes and/or cerebro-cardiovascular disease [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. But these previous reports targeted patients with only severe diabetes and/or cerebro-cardiovascular disease. It is also very important to investigate patients with less risk for these diseases. Here, the ASUCA trial was conducted to examine if atorvastatin could be more protective than other conventional therapy other than statins in preventing the progression of renal disease in Japanese patients with CKD and hyperlipidemia. There was no significant difference in eGFR at the time after 24&#x000a0;months.</p><p id="Par19">Lipid lowering effect of atorvastatin seems more potent than that of conventional therapy as it took just 1&#x000a0;month for atorvastatin to reduce serum LDL to the target level in Group A. Likewise, atorvastatin treatment, as opposed to conventional therapy, was able to reduce serum triglyceride level significantly. Thus, we expected that atorvastatin might be more protective in renal function.</p><p id="Par20">However, the effect of atorvastatin did not show a better renal protection at the time after 24&#x000a0;months compared to conventional treatment. De Zeeuw et al. suggested that some protective effect of atorvastatin on the renal function [<xref ref-type="bibr" rid="CR15">15</xref>] while the ASUCA trial did not show the superior effect of atorvastatin to conventional treatment in terms of renal function for less risk patients. The background of subjects could be the reason of failure of atorvastatin to show beneficial effect. In the ASUCA trial, less than 10&#x000a0;% of our patients have cerebro-cardiovascular disease compared to the TNT and GREACE study with 100&#x000a0;% subject with this disease. Approximately 30&#x02013;35&#x000a0;% of subject has diabetes in our study while the CARDS study fulfills the entry criteria with diabetes [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. In addition, 70&#x000a0;% of patients were taking an established renal protective drug of RAAS inhibitors in our study. In turn, 79&#x000a0;% of patients in Group C had been administered ezetimibe. Since ezetimibe would have renal protective effect [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], it is likely that ezetimibe might be reno-protective as much as atorvastatin in this study [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par21">It is interesting that Group C exhibited less GFR reduction after 18&#x000a0;months while Group A still showed the progressive decline at that point. While the precise mechanism remains unclear, it is likely that a less reduction in GFR in control group could be attributed to the beneficial effects from lipid lowering drugs. In our protocol, subjects in Group C, but not in Group A were allowed to take any lipid lowering drugs other than statin after 3&#x000a0;months. And treatment rate with other lipid lowering drugs were significantly higher at the end of study compared to that at baseline in Group C (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Since it has been shown that lipid lowering drugs exhibit the renoprotective effects, it is likely that using lipid lowering drugs was associated with a slowing down of GFR reduction in control group.</p><p id="Par22">In conclusion, atorvastatin did not show reno-protective effect compare to conventional therapy for Japanese patients. The limitation of this study is that we could not compare the placebo control despite of the ethical issue. So, further investigation is needed to examine the effect of LDL lowering therapy on the reno-protection.</p></sec></body><back><ack><p>We thank all of the patients, physicians, medical staff, and other contributors to the ASUCA trial. Details of the members of the ASUCA trial group are as follows: Representative: Kazuwa Nakao; Steering committee: Genjiro Kimura, Hiroshi Makino, Atsunori Kashiwagi, Sadayoshi Ito, Masato Odawara, Masashi Mukoyama, Hiromi Rakugi, Toshikazu Nishio, Masahide Yo; Protocol committee: Kenji Ueshima, Daisuke Koya, Tethsuya Babazono, Masato Kasahara; Diet commissioner: Miyuki Imamoto, Yumiko Miura; Safty Monitoring Board and Event Evaluation committee: Shinji Kosugi, Kenji Moriyama; Study Statistician; Toshiya Sato; Test management center: Shinji Yasuno, Akira Fujimoto Shoko Todo, Junko Kobayashi, Mayumi Yamanaka, Kazunori Takagi.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Source funding</title><p id="Par23">The ASUCA trial was funded by Department of EBM Research Institute of Advancement of Clinical and Translational Science Kyoto University Hospital with an unrestricted grant from Pfizer Japan.</p></sec><sec id="FPar2"><title>Conflict of interest</title><p id="Par24">Honoraria: Genjiro Kimura (Takeda, Daiichi-Sankyo, Novartis and Taisho-Toyama companies), Masato Ksahara (Pfizer, Daiichi-Sankyo, Fuji companies), Kenji Ueshima (Pfizer company).</p><p>Grants received: Genjiro Kimura (Japan Labour Health and Welfare Organization).</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Atat</surname><given-names>FA</given-names></name><name><surname>Stas</surname><given-names>SN</given-names></name><name><surname>McFarlane</surname><given-names>SI</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name></person-group><article-title>The relationship between hyperinsulinemia, hypertension and progressive renal disease</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><issue>11</issue><fpage>2816</fpage><lpage>2827</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000133698.80390.37</pub-id><pub-id pub-id-type="pmid">15504934</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>J</given-names></name><name><surname>Kastelein</surname><given-names>JJ</given-names></name><name><surname>Bittner</surname><given-names>V</given-names></name><name><surname>Deedwania</surname><given-names>P</given-names></name><name><surname>Breazna</surname><given-names>A</given-names></name><name><surname>Dobson</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>DJ</given-names></name><name><surname>Zuckerman</surname><given-names>A</given-names></name><name><surname>Wenger</surname><given-names>NK</given-names></name><collab>Treating to New Targets Investigators</collab></person-group><article-title>Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study</article-title><source>Clin J Am Soc Nephrol.</source><year>2007</year><volume>2</volume><issue>6</issue><fpage>1131</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.2215/CJN.04371206</pub-id><pub-id pub-id-type="pmid">17942759</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athyros</surname><given-names>VG</given-names></name><name><surname>Mikhailidis</surname><given-names>DP</given-names></name><name><surname>Liberopoulos</surname><given-names>EN</given-names></name><name><surname>Kakafika</surname><given-names>AI</given-names></name><name><surname>Karagiannis</surname><given-names>A</given-names></name><name><surname>Papageorgiou</surname><given-names>AA</given-names></name><name><surname>Tziomalos</surname><given-names>K</given-names></name><name><surname>Ganotakis</surname><given-names>ES</given-names></name><name><surname>Elisaf</surname><given-names>M</given-names></name></person-group><article-title>Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study</article-title><source>Nephrol Dial Transpl</source><year>2007</year><volume>22</volume><issue>1</issue><fpage>118</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfl538</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandhu</surname><given-names>S</given-names></name><name><surname>Wiebe</surname><given-names>N</given-names></name><name><surname>Fried</surname><given-names>LF</given-names></name><name><surname>Tonelli</surname><given-names>M</given-names></name></person-group><article-title>Statins for improving renal outcomes: a meta-analysis</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><issue>7</issue><fpage>2006</fpage><lpage>2016</lpage><pub-id pub-id-type="doi">10.1681/ASN.2006010012</pub-id><pub-id pub-id-type="pmid">16762986</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fassett</surname><given-names>RG</given-names></name><name><surname>Robertson</surname><given-names>IK</given-names></name><name><surname>Ball</surname><given-names>MJ</given-names></name><name><surname>Geraghty</surname><given-names>DP</given-names></name><name><surname>Coombes</surname><given-names>JS</given-names></name></person-group><article-title>Effect of atorvastatin on kidney function in chronic kidney disease: a randomized double-blind placebo-controlled trial</article-title><source>Atherosclerosis.</source><year>2010</year><volume>213</volume><issue>1</issue><fpage>218</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2010.07.053</pub-id><pub-id pub-id-type="pmid">20810109</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueshima</surname><given-names>K</given-names></name><name><surname>Kasahara</surname><given-names>M</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Babazono</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Imamoto</surname><given-names>M</given-names></name><name><surname>Yasuno</surname><given-names>S</given-names></name><name><surname>Fujimoto</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>G</given-names></name><name><surname>Nakao</surname><given-names>K</given-names></name></person-group><article-title>Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial</article-title><source>Clin Exp Nephrol.</source><year>2013</year><volume>17</volume><issue>2</issue><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1007/s10157-012-0676-5</pub-id><pub-id pub-id-type="pmid">22948416</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Hirao</surname><given-names>K</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><collab>MEGA Study Group</collab></person-group><article-title>Pravastatin and cardiovascular risk in moderate chronic kidney disease</article-title><source>Atherosclerosis.</source><year>2009</year><volume>206</volume><issue>2</issue><fpage>512</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2009.03.031</pub-id><pub-id pub-id-type="pmid">19423108</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laufs</surname><given-names>U</given-names></name><name><surname>Gertz</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Nickenig</surname><given-names>G</given-names></name><name><surname>Bohm</surname><given-names>M</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Endres</surname><given-names>M</given-names></name></person-group><article-title>Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice</article-title><source>Stroke</source><year>2000</year><volume>31</volume><issue>10</issue><fpage>2442</fpage><lpage>2449</lpage><pub-id pub-id-type="doi">10.1161/01.STR.31.10.2442</pub-id><pub-id pub-id-type="pmid">11022078</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>JN</given-names></name><name><surname>Wilson</surname><given-names>DJ</given-names></name><name><surname>Neutel</surname><given-names>J</given-names></name><name><surname>Houston</surname><given-names>M</given-names></name><name><surname>Weinberger</surname><given-names>MH</given-names></name><name><surname>Grimm</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Smith</surname><given-names>DH</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name></person-group><article-title>Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia</article-title><source>Am J Hypertens</source><year>2009</year><volume>22</volume><issue>2</issue><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1038/ajh.2008.325</pub-id><pub-id pub-id-type="pmid">19057518</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006; 17; 47(2):332&#x02013;7.</mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzir</surname><given-names>Z</given-names></name><name><surname>Leibovitch</surname><given-names>E</given-names></name><name><surname>Vaknin</surname><given-names>H</given-names></name><name><surname>Schreiber</surname><given-names>L</given-names></name><name><surname>Berger</surname><given-names>E</given-names></name><name><surname>Matas</surname><given-names>Z</given-names></name><name><surname>Fux</surname><given-names>A</given-names></name><name><surname>Boaz</surname><given-names>M</given-names></name><name><surname>Briliant</surname><given-names>A</given-names></name><name><surname>Biro</surname><given-names>A</given-names></name></person-group><article-title>Effect of atorvastatin on IgA nephropathy in the rat</article-title><source>Clin Nephrol</source><year>2013</year><volume>79</volume><issue>3</issue><fpage>214</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.5414/CN107621</pub-id><pub-id pub-id-type="pmid">23073067</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Shibata T, Tamura M, Kabashima N, Serino R, Tokunaga M, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y, Takeuchi M, Abe H, Okazaki M, Otsuji Y. Fluvastatin attenuates IGF-1-induced ERK1/2 activation and cell proliferation by mevalonic acid depletion in human mesangial cells. Life Sci. 2009; 22; 84(21&#x02013;22):725&#x02013;31.</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimojima</surname><given-names>M</given-names></name><name><surname>Kawashiri</surname><given-names>MA</given-names></name><name><surname>Nitta</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Katsuda</surname><given-names>S</given-names></name><name><surname>Kaku</surname><given-names>B</given-names></name><name><surname>Taguchi</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>A</given-names></name><name><surname>Konno</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Yamagishi</surname><given-names>M</given-names></name></person-group><article-title>Rapid changes in plaque composition and morphology after intensive lipid lowering therapy: study with serial coronary CT angiography</article-title><source>Am J Cardiovasc Dis.</source><year>2012</year><volume>2</volume><issue>2</issue><fpage>84</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">22720196</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bustos</surname><given-names>C</given-names></name><name><surname>Hernandez-Presa</surname><given-names>MA</given-names></name><name><surname>Ortego</surname><given-names>M</given-names></name><name><surname>Tunon</surname><given-names>J</given-names></name><name><surname>Ortega</surname><given-names>L</given-names></name><name><surname>Perez</surname><given-names>F</given-names></name><name><surname>D&#x000ed;az</surname><given-names>C</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>G</given-names></name><name><surname>Egido</surname><given-names>J</given-names></name></person-group><article-title>HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis</article-title><source>J Am Coll Cardiol</source><year>1998</year><volume>32</volume><issue>7</issue><fpage>2057</fpage><lpage>2064</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(98)00487-2</pub-id><pub-id pub-id-type="pmid">9857893</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Zeeuw</surname><given-names>D</given-names></name><name><surname>Anzalone</surname><given-names>DA</given-names></name><name><surname>Cain</surname><given-names>VA</given-names></name><name><surname>Cressman</surname><given-names>MD</given-names></name><name><surname>Heerspink</surname><given-names>HJ</given-names></name><name><surname>Molitoris</surname><given-names>BA</given-names></name><name><surname>Monyak</surname><given-names>JT</given-names></name><name><surname>Parving</surname><given-names>HH</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name><name><surname>Vidt</surname><given-names>DG</given-names></name></person-group><article-title>Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial</article-title><source>Lancet Diabetes Endocrinol.</source><year>2015</year><volume>3</volume><issue>3</issue><fpage>181</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(14)70246-3</pub-id><pub-id pub-id-type="pmid">25660356</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colhoun</surname><given-names>HM</given-names></name><name><surname>Betteridge</surname><given-names>DJ</given-names></name><name><surname>Durrington</surname><given-names>PN</given-names></name><name><surname>Hitman</surname><given-names>GA</given-names></name><name><surname>Neil</surname><given-names>HA</given-names></name><name><surname>Livingstone</surname><given-names>SJ</given-names></name><name><surname>Charlton-Menys</surname><given-names>V</given-names></name><name><surname>DeMicco</surname><given-names>DA</given-names></name><name><surname>Fuller</surname><given-names>JH</given-names></name><collab>CARDS Investigators</collab></person-group><article-title>Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the collaborative atorvastatin diabetes study (CARDS)</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>54</volume><issue>5</issue><fpage>810</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2009.03.022</pub-id><pub-id pub-id-type="pmid">19540640</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>Y</given-names></name><name><surname>Murayama</surname><given-names>T</given-names></name><name><surname>Minami</surname><given-names>M</given-names></name><name><surname>Matsubara</surname><given-names>T</given-names></name><name><surname>Yokode</surname><given-names>M</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name></person-group><article-title>Ezetimibe ameliorates early diabetic nephropathy in db/db mice</article-title><source>J Atheroscler Thromb.</source><year>2012</year><volume>19</volume><issue>7</issue><fpage>608</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.5551/jat.11312</pub-id><pub-id pub-id-type="pmid">22498767</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Hirano</surname><given-names>T</given-names></name></person-group><article-title>Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol</article-title><source>Metabolism.</source><year>2012</year><volume>61</volume><issue>3</issue><fpage>379</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2011.07.004</pub-id><pub-id pub-id-type="pmid">21868047</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>T</given-names></name><name><surname>Morimoto</surname><given-names>S</given-names></name><name><surname>Nakano</surname><given-names>C</given-names></name><name><surname>Kubo</surname><given-names>R</given-names></name><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Seo</surname><given-names>M</given-names></name><name><surname>Someya</surname><given-names>K</given-names></name><name><surname>Nakahigashi</surname><given-names>M</given-names></name><name><surname>Ueda</surname><given-names>H</given-names></name><name><surname>Toyoda</surname><given-names>N</given-names></name><name><surname>Kusabe</surname><given-names>M</given-names></name><name><surname>Jo</surname><given-names>F</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Iwasaka</surname><given-names>T</given-names></name><name><surname>Shiojima</surname><given-names>I</given-names></name></person-group><article-title>Renal and vascular protective effects of ezetimibe in chronic kidney disease</article-title><source>Intern Med</source><year>2014</year><volume>53</volume><issue>4</issue><fpage>307</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.53.0649</pub-id><pub-id pub-id-type="pmid">24531086</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouvelos</surname><given-names>GN</given-names></name><name><surname>Arnaoutoglou</surname><given-names>EM</given-names></name><name><surname>Milionis</surname><given-names>HJ</given-names></name><name><surname>Raikou</surname><given-names>VD</given-names></name><name><surname>Papa</surname><given-names>N</given-names></name><name><surname>Matsagkas</surname><given-names>MI</given-names></name></person-group><article-title>The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery</article-title><source>Angiology.</source><year>2015</year><volume>66</volume><issue>2</issue><fpage>128</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1177/0003319713519492</pub-id><pub-id pub-id-type="pmid">24458801</pub-id></element-citation></ref></ref-list></back></article>